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Summary
Objective: To test the mechanisms by which adenosine and adenosine analogues stimulate adenylate cyclase and suppress lipopoly-
saccharide (LPS)-induced production of nitric oxide (NO) by chondrocytes.
Methods: Primary chondrocytes isolated from equine articular cartilage were plated in monolayer. Intracellular cyclic-AMP (cAMP)
accumulation was measured following exposure to medium containing adenosine, the non-hydrolyzable adenosine analogue
N6-methyladenosine, the A2A specific agonist N6-(dimethoxyphenyl)-ethyl]adenosine (DPMA), the adenosine deaminase inhibitor erythro-
9-(2-Hydroxy-3-nonyl)adenine hydrochloride (EHNA), or forskolin, a potent stimulator of adenylate cyclase. Regulation of NO production by
LPS-stimulated chondrocytes, as determined by nitrite concentration, was assessed in the presence of adenosine, N6-methyladenosine,
DPMA, the broad agonist 5′-N-ethylcarboxamidoadenosine (NECA), or forskolin. Alternatively, LPS-stimulated chondrocytes were exposed
to EHNA or the phosphodiesterase inhibitor rolipram in the presence or absence of supplemental adenosine.
Results: Adenosine, N6-methyladenosine, DPMA, and forskolin each increased intracellular cAMP accumulation in a concentration-
dependent manner and suppressed NO production by LPS-stimulated chondrocytes. NECA also decreased NO production by chondrocytes
stimulated with LPS. Incubation with EHNA, to protect endogenously produced adenosine, or rolipram, which prevents the degradation of
cAMP, similarly suppressed LPS-stimulated NO production. The addition of exogenous adenosine with EHNA or rolipram further suppressed
NO production.
Conclusions: This study documents functional responses to adenosine by articular chondrocytes. These responses are mimicked by the A2A
receptor agonist, DPMA. Effects were enhanced by protecting adenosine using an adenosine deaminase inhibitor or by potentiating the
cAMP response with rolipram. These experiments suggest that adenosine may play a physiological role in regulation of chondrocytes and
that adenosine pathways could represent a novel target for therapeutic intervention. © 2002 OsteoArthritis Research Society International
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Chronic inflammation is a significant factor in the patho-
physiology of many forms of joint disease. Both rheumatoid
arthritis (RA) and osteoarthritis (OA), the most commonly
diagnosed arthritic conditions1, are inflammatory diseases
of the joint1–3. The purine base adenosine has been
reported to reduce inflammation and swelling in several
in vivo models of inflammation4–6. Additionally, daily sys-
temic treatment with adenosine reduced the severity of
adjuvant-induced arthritis in a rat model7. These findings
suggest the potential value of adenosine as a therapeutic
mediator of inflammatory joint disease. However, very little
work has been done documenting the effects of purines on
chondrocytes and additional documentation of the role of
adenosine in the joint is warranted.34Adenosine has been shown to limit systemic inflamma-
tory responses through receptor-mediated regulation of a
wide variety of cell types. For example, adenosine sup-
presses monocyte phagocytosis8 and inhibits neutrophil
functions including adhesion, degranulation and production
of reactive oxygen species9–11. In addition, extracellular
adenosine restricts T cell receptor signaling preventing T
cell activation and growth12,13. Inflammatory-mediated
changes in vascular permeability are also blocked by
adenosine, thereby reducing edema formation and restrict-
ing movement of immune cells from the vasculature14,15.
One of the best documented antiinflammatory functions
of adenosine is its ability to regulate cytokine synthesis.
The production of proinflammatory cytokines including
tumor necrosis factor- (TNF-)16,17, interleukin-8 (IL-8)18,
macrophage inflammatory protein-1, IL-2 and IL-619
are suppressed by exposure to adenosine or adenosine
analogs. Conversely, exposure to adenosine increases
synthesis of IL-1020, a potent regulator of macrophage
function.
In addition to its effects on the immune system, adeno-
sine is also recognized as a critical intercellular mediator in
other organ systems. For example, adenosine is an import-
ant neuromodulator in the central and peripheral nervous
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MATERIALS
Cyclic-AMP enzyme immunoassay (EIA) kits were pur-
chased from Amersham Pharmacia (Piscataway, NJ,U.S.A.). The fluorescent DNA quantitation kit was obtained
from Biorad (Hercules, CA, U.S.A.). Gentamicin sulfate
was produced by Schering-Plough Animal Health Corp.
(Madison, NJ, U.S.A.). Amphotericin B, fetal calf serum
(FCS) and Dulbecco’s modified Eagle’s Medium-Ham’s
F-12 nutrient medium (DMEM F-12) were purchased from
Gibco-BRL (Grand Island, NY, U.S.A.). Type-II collagenase
was purchased from Worthington Biochemical (Freehold,
NJ, U.S.A.). All other chemicals, including adenosine and
adenosine receptor agonists, were purchased from Sigma
(St. Louis, MO, U.S.A.) or Sigma-RBI (Natick, MA, U.S.A.).
Of the tested reagents, N6-methyladenosine is a substi-
tuted adenosine derivative that is resistant to breakdown by
adenosine deaminase41 (Table I). Synthetic adenosine
analogs used in this study also include N6-[2-(3,5-
dimethoxyphenyl)-ethyl]adenosine (DPMA), an A2A specific
receptor agonist42, and the nonselective A2 and A1 receptor
agonist 5′-N-ethylcarboxamidoadenosine (NECA)43. The
adenine analogue erythro-9-(2-Hydroxy-3-nonyl)adenine
hydrochloride (EHNA) is a potent inhibitor of adenosine
deaminase and was used to extend the half-life of both
supplemental and endogenous adenosine44. Forskolin is a
plant derivative that binds the stimulatory subunit of
adenylate cyclase directly stimulating cAMP production45.
This compound was used in this study as a positive control
for cAMP production by chondrocytes. The cAMP-specific
phosphodiesterase (Type IV) inhibitor rolipram was used to
extend the half-life of cAMP46 so that it could be measured
and to enhance the potential cAMP-mediated effects of
adenosine on NO production. The bacterial lipopolysac-
charide (LPS) used in this study was obtained from
Escherichia coli serotype 0111:B4.Table I
Pharmacological effects of purinergic reagents
Drug Action
Adenosine Extracellular purine receptor agonist
N6-methyladenosine Non-hydrolyzable analogue of adenosine
DPMA Adenosine A2A receptor agonist
NECA Adenosine A2 and A1 receptor agonist
Forskolin Direct adenylate cyclase activator
EHNA Adenosine deaminase inhibitor
Rolipram cAMP-specific phosphodiesterase inhibitorCELL ISOLATION AND PLATING
Full-thickness equine articular cartilage was aseptically
dissected from the metacarpophalangeal joints of fresh
equine cadavers as previously described47,48. Cartilage
samples were harvested from nine horses ranging from
2 to 10 years of age. Cartilage was collected in a sterile
mixture of DMEM F-12 containing 5% FCS, 2.5 g/ml
amphotericin B, 50 g/ml ascorbate, 100 U/ml penicillin,
100 g/ml streptomycin and 50 g/ml gentamicin sulfate.
Following dissection, cartilage samples were rinsed
once with fresh DMEM F-12 medium and subsequently
exposed to a three-step enzymatic digestion to free the
chondrocytes from the extracellular matrix. Cartilage was
incubated at 37°C for 15 min with 0.1% (w/v) type-I-S
hyaluronidase followed by incubation for 1 h with 0.1%
(w/v) type-XIV bacterial protease. Cartilage samples were
then incubated overnight at 37°C in 0.1% (w/v) type-II
collagenase. Following digestion, the medium was passed
through a 70 m cell strainer to remove undigested debris.systems. Adenosine release has been measured from
dorsal spinal cord21 and is known to have profound anti-
convulsant and analgesic effects21–23. Adenosine also
regulates cardiovascular function, influencing both heart
rate and blood flow24–27. Stimulation of adenosine recep-
tors has also been shown to reduce renal injury in an
ischemia-reperfusion model28. Although many cell types
have been shown to respond to extracellular adenosine,
the effects of adenosine on chondrocytes have not been
investigated in detail.
Extracellular purine receptors are divided into two
classes: P1 receptors, which preferentially bind adenosine,
and P2 receptors, which bind ATP and ADP with greater
affinity29. Both P1 and P2 receptors have been identified on
the surface of human chondrocytes30 and P2 receptors on
the surface of human synovial cells31. Adenosine receptors
of the P1 class have been further classified into four
subtypes (A1, A2A, A2B, A3) based on pharmacological
analysis and molecular cloning32. The A1 and A3 receptor
subclasses are negatively coupled to adenylate cyclase
and exert an inhibitory effect on cyclic-AMP (cAMP) pro-
duction. The A2 receptors, which stimulate adenylate
cyclase and increase cAMP, have been subdivided into
high affinity receptors (A2A) and low affinity receptors(A2B)32. The possible coexistence of multiple subclasses of
adenosine receptors on the surface of articular chondro-
cytes complicates elucidation of the mechanisms involved
with cellular responses to adenosine. Previous work has
already documented the expression of adenosine receptor
gene transcripts by articular chondrocytes30, but chondro-
cyte responses to adenosine receptor stimulation have not
been documented.
The potential antiinflammatory effects of adenosine in
the joint can be evaluated by examining the production of
inflammatory mediators, including nitric oxide (NO). The
enzyme nitric oxide synthase (NOS) exists in two constitu-
tive forms (cNOS) as well as an inducible form (iNOS)33.
Cells expressing cNOS regulate physiological functions by
transiently producing small amounts of NO while those
expressing iNOS produce larger quantities of NO for a
more prolonged period of time33. In diarthrodial joints,
chondrocytes express iNOS and are the major source of
intraarticular NO production34,35. The synthesis of NO by
articular cells is increased in vitro in response to inflamma-
tory stimuli such as bacterial lipopolysaccharide (LPS) or
IL-133,36. Several reports indicate that a large increase of
NO in the joint can be linked to inflammation resulting
in decreased chondrocyte proliferation and decreased pro-
teoglycan and collagen synthesis37–40. Altering chondro-
cyte production of NO could be key in retarding the joint
destruction that results from inflammatory disease.
The purpose of the current investigation was to docu-
ment functional roles for adenosine in articular chondro-
cytes and to determine if the A2 receptor subtype was
involved in that response. The study also examines the
effects of prolonging adenosine and cAMP exposure
times using the non-hydrolyzable adenosine analogue
N6-methyladenosine, the adenosine deaminase inhibitor
EHNA and the cAMP-specific phosphodiesterase (Type IV)
inhibitor rolipram.
36 A. M. Tesch et al.: Chondrocyte response to adenosine exposureReleased chondrocytes were collected by centrifugation at
230 g for 6 min, resuspended in fresh medium and counted
using a hemacytometer. Freshly isolated chondrocytes
were plated in 24- and 48-well plates at a density of
5×105 cells/cm2. Tissue culture plates were incubated in a
humidified atmosphere of 95% air/5% CO2 at 37°C.CAMP ASSAY
Chondrocytes from three horses (N=3) were used to
evaluate intracellular cAMP accumulation in response to
adenosine and its synthetic analogues. Cells were exposed
to either adenosine, DPMA or N6-methyladenosine, at
concentrations ranging from 0.1 to 100 M. In other wells,
chondrocytes were exposed to the adenosine deaminase
inhibitor EHNA at concentrations ranging from 0.01 to
10 M both alone and in the presence of 100 M adeno-
sine. Chondrocytes were also incubated with concen-
trations of forskolin ranging from 0.01 to 10 M as a
positive control for cAMP production. Negative control wells
were incubated with medium without added reagents.
Plated cells were allowed to stabilize in medium contain-
ing 5% FCS for 48 h prior to exposure to purinergic
reagents. Following the stabilization period, cells were
allowed to equilibrate in fresh serum-free medium for
20 min and subsequently incubated for 20 min in the pres-
ence of rolipram at a final concentration of 100 M. The test
reagent was then added to the test wells containing
rolipram and the plate was incubated at 37°C for 9 min
before the supernatant was removed and discarded. The
reaction was terminated at 10 min by the addition of 1.0 ml
of lysis buffer (0.25% dodecyltrimethylammonium bromide)
to each dry well.
Intracellular production of cAMP was subsequently
measured using a commercial EIA kit. Tissue culture plates
were placed on an orbital shaker at room temperature at
150 rpm for 10 min. An aliquot of cell lysate from each well
was then diluted 1:50 in lysis buffer and 100 l of each
sample was pipetted in duplicate to the 96-well EIA plate.
The tissue culture plate with the remaining lysate was
stored at −20°C until DNA content was measured.
The EIA plate was incubated at 4°C for 2 h with the
primary antibody and incubated for an additional 1 h at the
same temperature after the addition of cAMP-horseradish
peroxidase conjugate. The plate was rinsed four times with
wash buffer (0.01 M phosphate buffer, pH 7.5 containing
0.05% Tween 20) and 3,3′,5,5′-tetramethylbenzidine/
hydrogen peroxide in 20% (v/v) dimethylformamide was
added as an enzyme substrate. The plate was placed on an
orbital shaker at 100 rpm for 1 h at room temperature.
Following the addition of 1.0 M sulfuric acid, the optical
density was determined spectrophotometrically within
30 minutes using a microplate reader at 450 nm.NO ASSAY
Chondrocytes from three horses (N=3) were used to
evaluate the effects of adenosine and its synthetic
analogues on NO production. The purine reagents were
tested alone to determine their effect on baseline NO
production by unstimulated chondrocytes. In addition, the
reagents were tested in medium containing 100 g/ml LPS
to determine the effects of adenosine and its analogs on
chondrocytes exposed to a known stimulus of NO produc-
tion. For the purpose of this report, chondrocytes exposedto LPS will be referred to as LPS-stimulated chondrocytes
while those cultured without LPS will be termed unstimu-
lated. Both adenosine and N6-methyladenosine were
tested at 100 M, while DPMA and NECA were tested at a
concentration of 10 M. Additionally, forskolin, a positive
control for cAMP production, was tested at a concentration
of 1 M to determine whether elevation in intracellular
cAMP levels were responsible for observed purinergic
effects on NO synthesis. These concentrations were
selected based on reagent concentrations that were shown
to significantly increase cAMP accumulation in the first
phase of this study. Cells stimulated with LPS but not
exposed to any other reagent served as a positive control
for NO production. Cells maintained in tissue culture
medium without LPS or any other reagents served as
negative controls.
Using cells obtained from three horses (N=3), chondro-
cytes in tissue culture medium without LPS and chondro-
cytes activated with LPS were exposed to either EHNA
or rolipram at concentrations ranging from 1 to 100 nM.
Both EHNA and rolipram were tested alone and with the
coaddition of 100 M adenosine. The positive and negative
controls included were identical to those chosen for the first
series of NO experiments.
Nitric oxide has a short half-life in biological fluids or
culture medium. However, nitrite, a stable end product of
NO, can be measured using a spectrophotometric method
based on the Griess reaction49. The ratio of nitrite
concentration to total NO generated is stable in chondro-
cyte cultures, and nitrite levels can be used to accurately
estimate NO concentration50,51.
Cells were plated onto 48-well plates in media containing
the selected purinergic reagent and were allowed to attach
for 24 h prior to the addition of LPS. The plating medium
was then aspirated and replaced with fresh medium con-
taining the same purinergic reagents. Half of the wells from
each sample set were also treated with 100 g/ml LPS.
After an additional 24 h incubation period, medium was
removed and 200 l of 0.5 M NaOH was added to each
well. The supernatant media and tissue culture plates
containing lysed cells were stored individually at −20°C
until samples were analysed for NO and DNA content,
respectively.
Media aliquots of 50 l were pipetted into a clear-
bottomed 96-well plate and 50 l of freshly mixed Griess
reagent was added. After 5 min of agitation at low speed on
an orbital shaker, NO concentration was determined by
measuring optical density using a 96-well microplate reader
at a wavelength of 570 nm.DNA ASSAY
The total DNA content of chondrocytes per well was
determined using the Hoechst dye assay modified for use
with a 96-well fluorescent plate reader52. Plates were
thawed at room temperature for approximately 45 min on
an orbital shaker. Aliquots of cell lysate from the cAMP and
NO assays were mixed with a solution of 2 g/ml Hoechst
dye. After a five minute incubation at room temperature,
fluorescence was measured at an excitation wavelength of
360 nm and an emmision wavelength of 460 nm.STATISTICAL ANALYSIS
All values are expressed as mean±standard error of the
mean (S.E.M.). Values were reported as significant when
Osteoarthritis and Cartilage Vol. 10, No. 1 37P<0.05. Data were analysed using a two-way analysis of
variance (ANOVA) that was blocked by horse to allow
comparisons between reagents. When the ANOVA indi-
cated that the model was significant, post-hoc means
comparisons were performed to determine differences
between individual groups. For the cAMP experiments in
which reagents were added individually, the differences
between control measurements and treatment measure-
ments were performed using a Dunnett’s test (P<0.05).
Alternatively, for the experiments in which reagents were
added alone and in combination, data pairs were compared
using both the Student’s t-test with statistical significance
accepted at P<0.05 and the more stringent Bonferroni’s
procedure. The Bonferroni adjustment was used to protect
against type I errors, and the level of statistical acceptance
was based on the number of means comparisons per-
formed. All analysis was performed using SAS 8 statisti-
cal software package (SAS Institute, Cary, NC, U.S.A.).ResultsEFFECTS OF ADENOSINE ANALOGUES ON CAMP ACCUMULATION
Chondrocytes accumulated elevated levels of cAMP
when exposed to adenosine at concentrations ranging from1 to 100 M, but not at the lowest concentration tested
[Fig. 1(a)]. The magnitude of the response to adenosine
was concentration dependent. The non-hydrolyzable
adenosine analogue N6-methyladenosine significantly
increased cAMP accumulation by chondrocytes at concen-
trations of 10 and 100 M but not at 0.1 or 1 M [Fig. 1(b)].
In a similar manner, the A2A specific agonist DPMA signifi-
cantly increased cAMP accumulation in chondrocytes when
cells were exposed to concentrations from 0.1 to 10 M but
not at 100 M [Fig. 1(c)]. Forskolin, which directly stimu-
lates adenylate cyclase, strongly increased cAMP accumu-
lation when added at concentrations from 0.01 to 10 M
[Fig. 1(d)]. Levels of cAMP detected in the presence of
forskolin were approximately 20 times higher than those
detected in response to purine receptor agonists.0
10
DPMA (µM)
C
pm
ol
 c
A
M
P
/µ
g 
D
N
A
9
1001010.10
*
*
*
0
100
Forskolin (µM)
D
pm
ol
 c
A
M
P
/µ
g 
D
N
A
90
10.01.00.10.010
*
*
*
0
20
Adenosine (µM)
A
pm
ol
 c
A
M
P
/µ
g 
D
N
A
18
1001010.10
*
*
*
0
8
N6-methyldenosine (µM)
B
pm
ol
 c
A
M
P
/µ
g 
D
N
A
7
1001010.10
*
*
8
7
6
5
4
3
2
1
80
70
60
50
40
30
20
10
16
14
12
10
8
6
4
2
6
5
4
3
2
1
Fig. 1. Intracellular cAMP accumulation by equine chondrocytes cultured in monolayer and exposed to selected reagent for 10 min prior to
cell lysis. Data were collected from chondrocytes obtained from a single horse, but are representative of results from three horses. A
significant increase in cAMP accumulation (*) occurred with exposure to (a) adenosine at concentrations of 1 to 100 M (P<0.05) (b)
N6-methyladenosine at concentrations of 10 and 100 M (P<0.05) (c) DPMA at concentrations of 0.1 to 10 M (P<0.05) and (d) forskolin at
concentrations of 0.01 to 10 M (P<0.05). All cells were incubated in the presence of 100 M rolipram, a type IV phosphodiesterase inhibitor.EFFECTS OF EHNA AND ROLIPRAM ON CAMP ACCUMULATION
Chondrocytes exposed to EHNA, an enzyme inhibitor
that prevents the breakdown of adenosine, did not accu-
mulate increased levels of cAMP. However, exposure to
EHNA at concentrations ranging from 0.1 to 10 M
increased cAMP accumulation in chondrocytes that were
simultaneously exposed to 100 M adenosine (Fig. 2). This
38 A. M. Tesch et al.: Chondrocyte response to adenosine exposureincrease in cAMP accumulation was significantly higher
than the increase in intracellular cAMP accumulation
measured in response to incubation with adenosine alone.
In contrast, cells incubated with a lower concentration
of EHNA (0.01 M) did not significantly increase cAMP
accumulation when exposed to 100 M adenosine.
In all cases, supplementation with the type IV cAMP-
specific phosphodiesterase inhibitor rolipram was required
for experimental detection of cAMP accumulation. If
rolipram was not added to the tissue culture wells during
the incubation period, the accumulation of cAMP was
below the detection threshold of the assay (<1 pmol/g
DNA) regardless of the reagent added. For example, cells
exposed to 1 M forskolin and treated with rolipram accu-
mulated the highest measured levels of cAMP at
17.6±0.4 pmol of cAMP per g DNA. However, when
chondrocytes from the same horse were exposed to 1 M
forskolin in the absence of rolipram the intracellular levels
of cAMP were below the detection threshold of the assay.
In addition, chondrocytes that were not exposed to any
exogenous purinergic reagents accumulated a small but
measurable level of cAMP in the presence of rolipram
alone.EFFECTS OF ADENOSINE ANALOGUES ON LPS-STIMULATED NO
PRODUCTION
Chondrocytes exposed to 100 g/ml LPS for 24 h
increased production of NO by approximately 10-fold over
the baseline levels produced by unstimulated chondrocytes
(Fig. 3). Nitric oxide production by unstimulated chondro-
cytes was minimal. Treatment of LPS-stimulated chondro-
cytes with 100 M adenosine or N6-methyladenosine
inhibited this increase in NO production (Fig. 3). In addition,
10 M of either the non-selective adenosine receptor
agonist NECA or the A specific agonist DPMA also2Asignificantly decreased NO production by chondrocytes
stimulated with LPS (Fig. 3). Exposure to 1 M forskolin
also suppressed chondrocyte NO release in response to
LPS stimulation (Fig. 3). Adenosine, N6-methyladenosine,
DPMA, NECA, and forskolin all inhibited LPS-stimulated
NO synthesis to a similar degree. Exposure to
N6-methyladenosine, NECA, DPMA, or forskolin alone did
not significantly alter NO production by chondrocytes that
were not cultured in the presence of LPS (data not shown).
Cells cultured without LPS did, however, increase NO
synthesis when exposed to 100 M adenosine but NO
levels were approximately 1:10 of the levels produced in
the presence of LPS (Fig. 4).0
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Fig. 2. Intracellular cAMP accumulation by equine chondrocytes
cultured in monolayer and exposed simultaneously to EHNA and
adenosine for 10 min prior to cell lysis. Data were collected from
chondrocytes obtained from a single horse, but are representative
of results from three horses. Control wells had no reagents added.
A significant increase in cAMP accumulation (*) occurred with
simultaneous exposure to 100 M adenosine and EHNA at con-
centrations of 0.1 to 10 M when compared to cAMP accumulation
seen in response to adenosine alone (P<0.0024). All cells were
incubated in the presence of 100 M rolipram, a type IV phos-
phodiesterase inhibitor.0
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Fig. 3. Inhibition of LPS-stimulated NO production by adenosine
and its synthetic analogues. Treatments are as follows: column (1)
control–no reagents added; column (2) 100 g/ml LPS alone;
column (3) 100 M adenosine+100 g/ml LPS; column (4) 100 M
N6-methyladenosine+100 g/ml LPS; column (5) 10 M NECA+
100 g/ml LPS; column (6) 10 M DPMA+100 g/ml LPS; and
column (7) 1 M forskolin+100 g/ml LPS. Data were collected
from chondrocytes obtained from a single horse, but are represen-
tative of results from three horses. A significant decrease in
LPS-mediated NO production (*) occurred with exposure to all of
the tested purinergic reagents (P<0.0019).EFFECTS OF EHNA AND ROLIPRAM ON LPS-STIMULATED NO
PRODUCTION
The addition of 1 to 100 nM EHNA decreased the pro-
duction of NO by chondrocytes that were stimulated with
LPS (Fig. 5). Co-addition of 100 M adenosine with EHNA
resulted in a more profound inhibition of LPS-stimulated
NO production at all concentrations tested. The levels
of NO produced by chondrocytes exposed to all three
reagents simultaneously (LPS, EHNA and adenosine) were
significantly lower than those detected in the presence of
LPS alone, LPS and adenosine alone, or LPS and EHNA
alone (Fig. 5). This difference was significant at all
concentrations of EHNA tested. However, there was not a
statistically significant difference in NO levels between
each concentration of EHNA tested. The inhibition of
LPS-stimulated NO production detected in response to
coaddition of both EHNA and adenosine was roughly equal
to the combined responses observed with exposure to
each reagent supplemented individually. Nitric oxide pro-
duction by chondrocytes not exposed to LPS was not
Osteoarthritis and Cartilage Vol. 10, No. 1 39significantly altered in the presence of 1 to 100 nM EHNA or
by the coaddition of the same concentrations of EHNA and
100 M adenosine (Data not shown).
The addition of rolipram at concentrations of 1 to 100 nM
inhibited LPS-stimulated NO production by chondrocytes
(Fig. 6). Coaddition of 100 M adenosine with rolipram
resulted in a more profound inhibition of LPS-stimulated
NO production at all concentrations tested. The levels of
NO produced by chondrocytes exposed to all three re-
agents simultaneously (LPS, rolipram and adenosine) were
significantly lower than those detected in the presence of
LPS alone, LPS and adenosine alone, or LPS and rolipram
alone (Fig. 6). This difference was significant at all concen-
trations of rolipram tested. However, there was not astatistically significant difference in NO levels between
each concentration of rolipram tested. The inhibition of
LPS-stimulated NO production detected in response to
coaddition of both rolipram and adenosine was roughly
equal to the combined responses observed with exposure
to each reagent supplemented individually. Rolipram did
not significantly alter NO production by unstimulated
chondrocytes when tested at concentrations of 1 nM to
100 nM (data not shown). Unstimulated chondrocytes did
increase NO synthesis when exposed to both 100 M
adenosine and 100 nM rolipram simultaneously, but this
increase was not statistically different than the increase
detected in the presence of 100 M adenosine alone
(Fig. 4).0
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Fig. 4. Stimulation of NO production by adenosine. Data were
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representative of results from three horses. All samples were
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Fig. 5. Inhibition of LPS-stimulated NO production by EHNA. Data
were collected from chondrocytes obtained from a single horse,
but are representative of results from three horses. EHNA, at
concentrations of 1 to 100 nM, inhibited production of NO by
chondrocytes exposed to 100 g/ml LPS. Simultaneous exposure
to EHNA and 100 M adenosine resulted in a significant decrease
in (*) LPS-mediated NO production when compared to the
effect of adenosine alone or EHNA alone on LPS-induced
NO at all concentrations of EHNA tested (P<0.0012). LPS, ";
LPS+adenosine, h.0
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Fig. 6. Inhibition of LPS-stimulated NO production by rolipram.
Data were collected from chondrocytes obtained from a single
horse, but are representative of results from three horses.
Rolipram, at concentrations of 1 to 100 nM, inhibited production of
NO by chondrocytes exposed to 100 g/ml LPS. Simultaneous
exposure to rolipram and 100 M adenosine resulted in a signifi-
cant decrease in (*) LPS-mediated NO production when compared
to the effect of adenosine alone or rolipram alone on LPS-induced
NO at all concentrations of EHNA tested (P<0.05). LPS, ";
LPS+adenosine, h.Discussion
Previous studies have documented the presence of
adenosine receptor transcripts in articular chondrocytes30;
however, functional responses by these cells to extracellu-
lar adenosine have not been described in the literature. The
objective of this study was to establish whether adenosine
and its analogs were capable of altering cAMP and NO
production by articular chondrocytes, and to determine
which subclass or subclasses of adenosine receptors were
responsible for any observed biological responses. The
results of this study show that chondrocytes respond to
extracellular adenosine by increasing cAMP accumulation
in a concentration-dependent manner. This study also
demonstrated the ability of adenosine and adenosine
analogues to significantly inhibit LPS-induced production of
NO.
Measurement of intracellular cAMP levels was utilized
here to monitor the functional response of articular
chondrocytes to extracellular adenosine. An increase in
cAMP accumulation in response to extracellular adenosine
indicated the presence of active adenosine receptors on
the surface of articular chondrocytes. This increase further
40 A. M. Tesch et al.: Chondrocyte response to adenosine exposuresuggested involvement of the A2 adenosine receptor sub-
classes, which are known to activate adenylate cyclase32.
In contrast, the presence of A1 and A3 receptor subclasses
was not indicated by this response, as these subclasses
are negatively coupled to adenylate cyclase and would not
be expected to increase baseline cAMP accumulation.
However, the presence of A1 and A3 receptors on chondro-
cytes cannot be ruled out, as they were not investigated
further in this study. It is possible that all three subclasses
of adenosine receptors are present on the surface of
equine chondrocytes but that the A2 predominate, resulting
in increased cAMP accumulation.
Forskolin, which directly activated adenylate cyclase,
was utilized in this study as a positive control for cAMP
production. The levels of intracellular cAMP accumulated in
response to forskolin were much higher than the levels
detected following exposure to adenosine receptor agon-
ists, which was expected. Rolipram, a type IV phospho-
diesterase inhibitor that prevents the catabolism of cAMP,
was selected in this investigation for use in the cAMP assay
because of its ability to prevent the rapid degradation of
cAMP53,54, allowing the accurate detection of the cAMP
levels being produced. In this study, rolipram was essential
for the detection of any cAMP, even in the presence of
forskolin, a potent stimulator of adenylate cyclase.
The A2 subclass of adenosine receptors have been
further subdivided into the high affinity receptors, known as
the A2A, and the low affinity receptors, or A2B32. The
involvement of A2A receptors in the chondrocyte response
to extracellular adenosine demonstrated here is supported
by the increase in cAMP accumulation shown in response
to the A2A specific agonist DPMA. However, an increase in
cAMP accumulation was not detected with the highest
concentration of DPMA tested. It may be that such a high
concentration of this selective agonist is toxic or that DPMA
loses receptor specificity when present at high concen-
trations. Although the positive response to DPMA indicates
the presence of functioning A2A receptors on equine
chondrocytes, the presence of functioning A2B receptors
cannot be ruled out on the basis of this study. Distinguish-
ing between the activation of A2A and A2B receptors in this
study was complicated by the lack of a commercially
available A2B specific agonist.
It is well established that adenosine has a short half-life
in biological systems24 and this suggested that preventing
the rapid degradation of adenosine could enhance its
effects on chondrocytes. The adenosine analogue
N6-methyladenosine was chosen to investigate this hypoth-
esis, as it is a poor substrate for adenosine deaminase41,
which catalyses the breakdown of adenosine to inosine.
N6-methyladenosine increased the intracellular accumu-
lation of cAMP by primary articular chondrocytes in a
concentration-dependent manner but was not as effective
as adenosine in promoting cAMP accumulation. This is
consistent with previously published papers that report a
reduced ability of N6-methyladenosine to elicit physiological
responses linked to A2 receptors when compared to the
responses observed with adenosine55,56. It has also been
reported that N6-methyladenosine has a higher binding
constant, and thus a lower affinity, for both A1 and A2
receptors than adenosine57.
The adenosine deaminase inhibitor EHNA was also
selected for investigation in this study due to its ability to
slow the breakdown of adenosine. Chondrocytes exposed
to exogenous adenosine in the presence of EHNA demon-
strated an increased accumulation of intracellular cAMP
over cells exposed to adenosine alone. The results of thisstudy support the hypothesis that prolonged exposure to
adenosine by preventing its degradation does indeed result
in increased cAMP accumulation, as the adenosine
deaminase inhibitor EHNA is able to enhance adenosine-
mediated cAMP accumulation. The use of adenosine
kinase inhibitors may similarly prove to be effective at
protecting endogenously produced adenosine in the joint,
providing antiinflammatory benefits.
The antiinflammatory potential of adenosine is being
investigated in many other biological systems46,58. The
study described here utilized an in vitro model of the joint to
test the effects of adenosine on NO production by chondro-
cytes alone and in the presence of LPS, a proinflammatory
stimulus. Chondrocytes incubated in the presence of LPS
increased production of NO, as previously documented35.
Incubation with adenosine and adenosine analogues sig-
nificantly reduced production of NO by chondrocytes that
were simultaneously exposed to LPS. This reduction was
observed with adenosine, a broad adenosine receptor
agonist, NECA, or with the A2A specific agonist DPMA. The
ability of DPMA to reduce LPS-stimulated NO production
further supports the presence of functioning A2A receptors,
on equine chondrocytes.
In contrast to responses observed in the presence of
LPS, adenosine receptor agonists did not significantly alter
baseline NO production by chondrocytes that were not
exposed to LPS. This result was expected, as unstimulated
chondrocytes produce very low levels of baseline NO and
express negligible levels of iNOS35. However, exposure to
the highest concentration of adenosine tested did cause a
small increase in NO production. The NO levels measured
in response to the highest concentration of adenosine
alone were 10- to 20-fold lower than those seen in
response to LPS stimulation. The observed production of
low levels of NO with the addition of exogenous adenosine
in the absence of proinflammatory stimuli may be attributed
to the presence of adenosine receptor subclasses that both
stimulate and inhibit adenylate cyclase on the same cell
type. A high concentration of adenosine may be able to
saturate any A1, A2, and A3 receptors on the surface of
articular chondrocytes. Additional work will be required to
investigate the significance of the observed response to
high levels of adenosine.
The ability of adenosine to reduce LPS-induced NO
production appears to be at least partially mediated by the
accumulation of cAMP in response to adenosine receptor
activation. For example, forskolin, a direct stimulator of
adenylate cyclase, was able to decrease LPS-induced
NO synthesis in the absence of adenosine. Additionally,
rolipram, which inhibits the rapid degradation of cAMP by
phosphodiesterases, enhanced the adenosine-mediated
decrease in NO production by LPS-stimulated chondro-
cytes. The effects of cAMP accumulation in LPS-stimulated
chondrocytes are consistent with prior reports demonstrat-
ing that the production of cAMP has antiinflammatory
effects on neutrophils and that these effects were
enhanced by exposure to rolipram46,59.
Although this study suggests that an increase in adeno-
sine receptor-mediated cAMP is responsible for the
observed decrease in LPS-induced NO, the mechanism for
that association is not clear. Prior work in other cell types
has shown that cAMP activates protein kinase A (PKA),
which can signal through a variety of intermediate signaling
proteins60. For cAMP to decrease LPS-induced NO, as
demonstrated in this study, there is probably an effect of
PKA-mediated pathways on the signaling pathway that is
activated by LPS. Lipopolysaccharide is known to share a
Osteoarthritis and Cartilage Vol. 10, No. 1 41number of signaling proteins with IL-1 and TNF, and the
effect of cAMP may be on the transcription factor NFB,
which is activated by all three61. There is evidence that in
some cell types intracellular cAMP accumulation can inhibit
the activation of NFB62,63. Further study is necessary to
determine the specific mode of interaction that appears to
be occurring between the two signaling pathways in the
inhibition of NO production by chondrocytes.
In addition to the physiological effects mediated by
exogenously supplemented adenosine, these experiments
also suggest a possible role for endogenous adenosine on
chondrocytes. The suppression of LPS-induced NO syn-
thesis by EHNA alone, which prevents the normally rapid
enzymatic breakdown of adenosine, suggests that
chondrocytes may release physiologically significant levels
of adenosine when stimulated with LPS. Exposure to
EHNA alone did not significantly alter baseline production
of NO by unstimulated chondrocytes, but was able to
significantly inhibit the production of NO by chondrocytes
that were stimulated with LPS. This suggests that
endogenous adenosine may be released by chondro-
cytes exposed to inflammatory stimuli and that this adeno-
sine is able to interact with cell surface receptors and
subsequently reduce NO synthesis.
In this study, the phosphodiesterase inhibitor rolipram
suppressed NO production by chondrocytes that were
exposed to LPS but did not significantly alter the production
of NO by unstimulated chondrocytes. These findings sug-
gest that increased levels of cAMP are generated in the
presence of LPS but that this cAMP would be degraded in
the absence of rolipram. One explanation is that there may
be increased release of adenosine in response to LPS.
Released adenosine could then interact with cell surface
receptors in an autocrine or paracrine fashion and mediate
an increase in intracellular cAMP production. This sup-
position is supported by the inability of EHNA to increase
the concentration of intracellular cAMP when present
alone even though EHNA was shown to heighten cAMP
accumulation in response to adenosine. Additional studies
have been initiated to investigate the ability of chondro-
cytes to release adenosine, particularly when under the
influence of pro-inflammatory stimuli such as IL-1 or LPS.
To consider the physiological relevance of this study, it is
important to compare the levels of stimulation required to
elicit a response to the concentration of adenosine known
to be present in biological systems. Other studies have
demonstrated adenosine release at sites of inflammation at
concentrations up to 1 M in vivo64. The results of this
study demonstrate increased cAMP accumulation by
chondrocytes exposed to 1 M adenosine. It is certainly
possible that local concentrations of adenosine at sites of
joint inflammation may be even higher than those pre-
viously measured, as adenosine detection is complicated
by its very short half-life in biological systems24.
The data reported in this paper demonstrate some of the
functional effects of adenosine receptor stimulation on
equine articular chondrocytes. The therapeutic potential of
endogenous adenosine for down-regulating immune cell
mediated damage is already under investigation in other
systems11,15, but there is a critical need for more detailed
investigation of the role of exogenous and endogenous
adenosine in the joint. Additional studies are indicated to
examine the mechanism of action and release of adeno-
sine in the joint and to expand previous work to include
other species.Acknowledgments
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